Search Results
Your search for ASCO matches 21361 pages
Showing 20851 - 20900FDA Approves Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
The U.S. Food and Drug Administration (FDA) today expanded the approved use of ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy. Ibrutinib, an oral Bruton’s tyrosine kinase inhibitor, was previously...
Researchers Identify Biomarker for Noncancerous Pancreatic Cysts
Researchers at the Indiana University School of Medicine have discovered a highly accurate, noninvasive test to identify benign pancreatic cysts, which could spare patients the cost and risk of surveillance or potentially dangerous surgical intervention. The findings are reported in the Journal of...
Novel Photon-Counting Technique Increases Detection Rate in Screening Mammography
As mammography screening has shifted to digital technology, a range of computed radiography and direct radiography systems have emerged. Digital mammography screening with a new photon-counting technique offers high diagnostic performance, according to a study reported by Weigel et al in Radiology. ...
Brachytherapy Offers Lower Rate of Breast Preservation vs Standard Radiation for Older Women With Breast Cancer
When comparing treatments designed to enable long-term breast preservation for older women with invasive breast cancer, researchers found those treated with brachytherapy were at higher risk for a later mastectomy, compared to women treated with standard radiation therapy. The findings, published...
Obesity Linked to Poor Survival in Patients With Tongue Cancer
Cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College are collaborating to understand the link between obesity and cancer. Most recently, their research has yielded an interesting association: Obesity prior to diagnosis is associated with a fivefold increase...
Optimized Radiation Treatment Schedule for Glioblastoma May Extend Survival
An altered radiation treatment schedule for glioblastoma, the most common and lethal form of brain cancer, extended the survival period of mice with the disease, according to a new study published in Cell. Because the research involved mice, the study does not recommend a specific new schedule for...
Biomarker May Predict Response to Ipilimumab in Advanced Melanoma
Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy ipilimumab (Yervoy), according to a study by Yuan et al published in Cancer Immunology Research....
ASCO Issues New Recommendations for Family History-Taking in Oncology Setting
When oncologists see a new patient, they should emphasize careful documentation of first- and second-degree cancer family history, according to new recommendations published by the American Society of Clinical Oncology. The recommendations are the first to focus on family history-taking...
New Society Launched for Advanced Practitioners in Hematology and Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHO) announced its launch as a new organization focused on meeting the unique educational and professional needs of the advanced practitioner in hematology and oncology. The formation of the Society was made public January 26, 2014,...
Study Reports Success in Targeted Therapy for Lung Adenocarcinoma
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients. The study, published in...
Early Termination Not Unique to Genitourinary Cancer Clinical Trials
An analysis of 7,776 adult cancer clinical trials registered on Clinicaltrials.gov showed that approximately 20% of trials failed to be completed for reasons unrelated to the efficacy or side effects of the intervention. In 2010, a report from the Institute of Medicine entitled “A National...
Angiotensin System Inhibitors Improve Survival in Hypertensive Patients With Metastatic Renal Cell Carcinoma
According to a retrospective study, the use of angiotensin system inhibitors, such as lisinopril, captopril, and losartan, improved the survival of patients with metastatic renal cell carcinoma by 9 months, compared with patients who were not receiving these types of agents. Survival was even...
New Clues May Link Hereditary Cancer Genes to Increased Risk of Cancer From Alcohol
In laboratory experiments conducted on human cell lines at the Johns Hopkins Sidney Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by acetaldehyde, a ...
Melatonin May Potentially Slow Tumor Growth in Estrogen Receptor–Negative Breast Cancers
An early-stage study shows melatonin may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo. The study, published online in the journal PLoS...
ASCO Survey of Oncologists Finds High Overall Career Satisfaction, but Nearly Half Report Burnout
A survey of oncologists by Shanafelt et al has found that approximately 45% had at least one symptom of burnout, with risk being greatest among younger oncologists and those spending more hours per week devoted to direct patient care. However, overall career satisfaction remains high, especially...
Intensity-Modulated Radiation Therapy Improves Survival in Patients With Head and Neck Cancer
Patients with cancers of the head and neck who received intensity-modulated radiation therapy experienced improved outcomes, as well as reduced toxicities, compared to patients receiving conventional radiation therapy, according to findings published online in Cancer by Beadle et al. The study is...
Maintenance Capecitabine/Bevacizumab Delays Disease Progression in Metastatic Colorectal Cancer and Extends Survival in Subgroups
According to the final results of the phase III CAIRO3 trial by the Dutch Colorectal Cancer Group, maintenance treatment with capecitabine plus bevacizumab (Avastin) significantly delayed progression compared to observation in patients with metastatic colorectal cancer, and in a subset of patients, ...
Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer Patients With Liver Metastases
Irinotecan drug-eluting beads given simultaneously with FOLFOX (leucovorin, fluorouracil, oxaliplatin) and bevacizumab (Avastin) in patients with unresectable liver metastasis from colorectal cancer improved response rates, increased resectability and prolonged hepatic progression-free survival in...
Cetuximab Fails to Improve Survival in Nonoperable Esophageal Cancer
More data have emerged that discount the potential for benefit with epidermal growth factor receptor (EGFR) inhibitors in esophageal cancer. The latest comes from the RTOG 0436 randomized phase III trial in patients with nonoperable esophageal cancer, the results of which were presented at the 2014 ...
Immunotherapy Strategy Boosts Survival in Metastatic Pancreatic Cancer
Overall survival was improved in patients with metastatic pancreatic cancer through an innovative immunotherapy strategy in a multicenter study to be reported at the 2014 Gastrointestinal Cancers Symposium (Abstract 177). The results were announced at a press briefing prior to the meeting....
Ramucirumab Combination Improves Overall Survival After First Progression in Patients With Metastatic Gastric Cancer
In the global phase III RAINBOW trial of patients with metastatic gastric cancer, the investigational monoclonal antibody ramucirumab significantly improved both progression-free and overall survival when given as second-line therapy, investigators reported at a press briefing in advance of the...
RAS Status Predicts Response to Second-Line Treatment With Panitumumab for Metastatic Colorectal Cancer
New data from a phase III clinical trial shows that patients with metastatic colorectal cancer tumors that contain RAS mutations beyond KRAS exon 2 are unlikely to benefit from the addition of panitumumab (Vectibix) to second-line FOLFIRI (leucovorin, fluorouracil, irinotecan) chemotherapy....
Preoperative Oral Capecitabine Chemotherapy Is Equivalent to Infusional 5-FU for Rectal Cancer
New findings from a four-arm phase III clinical trial in patients with stage II or stage III rectal cancer indicate that combining preoperative radiation with either capecitabine or fluorouracil (5-FU) results in equivalent outcomes. This study provides strong clinical evidence that using either...
Combination Capecitabine/Temozolomide Appears Highly Effective in Patients With Treatment-Resistant Neuroendocrine Tumors
Interim results from an ongoing phase II clinical trial in patients with various types of advanced neuroendocrine tumors show that a new chemotherapy combination of capecitabine and temozolomide either stalled disease progression or shrank tumors in 95% of patients whose disease worsened after...
Dabrafenib Receives FDA Breakthrough Therapy Designation for BRAF-Mutated NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for dabrafenib (Tafinlar) for the treatment of patients with metastatic BRAF V600E mutation–positive non–small cell lung cancer (NSCLC) who have received at least one prior line of...
FDA Accepts New Drug Application for Idelalisib in Refractory Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for idelalisib, a targeted, oral inhibitor of PI3K-delta, for the treatment of refractory indolent non-Hodgkin lymphoma (NHL). The FDA has granted a standard review for the NDA, with a target review date of...
FDA Approves Combination Therapy for Unresectable or Metastatic Melanoma With BRAF V600E/K Mutations
The U.S. Food and Drug Administration (FDA) has approved trametinib (Mekinist) for use in combination with dabrafenib (Tafinlar) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved...
Major Decline in Lung Cancer Reported
“Eliminating tobacco use is the most important thing we can do to prevent lung and other cancers, as well as the many other diseases its use causes. Today’s news confirms that we are making progress. However, the global health challenges from tobacco are still growing. “This new...
Rates of New Lung Cancer Cases Drop in U.S. Men and Women
Tobacco control efforts are having a major impact on Americans’ health, a new analysis of lung cancer data suggests. The rate of new lung cancer cases decreased among men and women in the United States from 2005 to 2009, according to a report in this week’s Morbidity and Mortality...
ASCO Issues Statement in Response to American Cancer Society Report
Today the American Cancer Society issued a report showing a 20% decline in cancer death rates between 1991 and 2010, and estimating that 1.3 million deaths have been averted as a result of the decline. ASCO issued the following statement: “This is tremendous progress and a direct result ...
Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine
Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...
FDA Approves Revised Prescribing Information for Ponatinib, Authorizes Resumption of Drug Sales and Distribution
The U.S. Food and Drug Administration (FDA) has approved revised prescribing information and a Risk Evaluation and Mitigation Strategy (REMS) for ponatinib (Iclusig) that allows immediate resumption of its marketing and commercial distribution. The prescribing information includes a revised...
Julie M. Vose, MD, MBA, FASCO, Elected ASCO President for 2015-2016 Term
Julie M. Vose, MD, MBA, FASCO, has been elected President of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2015. She will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2014. Additionally, four new members were elected to the...
U.S. Cancer Death Rates Continue Decline, Annual Report Shows
Maintaining a 2 decade–long trend, the cancer death rate in the United States continues to decline, according to the Annual Report to the Nation on the Status of Cancer, published online this week in Cancer. The report, which covers the years 2001 to 2010, shows drops in death rates for a...
Dasatinib/Letrozole Drug Combination Delays Disease Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Adding dasatinib (Sprycel) to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented at the 2013 San Antonio Breast...
Benefit of Breast Cancer Screening More Consistent Across Studies Than Previously Understood
Re-examination of data from four large studies of the benefits and harms of mammography screening shows that the benefits are more consistent across these studies than previously understood and that all the studies indicate a substantial reduction in breast cancer mortality with screening,...
High Levels of Immune Cells in Tumors May Identify Breast Cancer Patients Most Likely to Benefit From Trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab (Herceptin), according to results presented today at the 2013 San Antonio Breast Cancer Symposium (Abstract S1-05)....
ASH 2013: Brentuximab Vedotin Shows Promising Activity in Non-Hodgkin Lymphoma
The antibody-drug conjugate brentuximab vedotin (Adcetris) has shown “compelling” antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, in a study presented at the American Society of Hematology (ASH) Annual Meeting and Exposition...
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Updated Myeloma Trial Shows Lenalidomide Maintenance Post-Transplant Improves Progression-Free But Not Overall Survival
A new analysis of the multiple myeloma IFM 2005-02 trial showed that lenalidomide (Revlimid) maintenance prolongs progression-free survival after stem cell transplantation, but does not improve overall survival. This is possibly attributed to the shorter survival time after first disease...
Vorinostat Plus Standard Immunoprophylaxis Cuts Risk of Graft-vs-Host Disease in Half
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of bone marrow transplant treatments, according to a study by Choi et al published in The Lancet Oncology. The study, the first to test this treatment in humans, combined the drug vorinostat...
Digital Breast Tomosynthesis Increases Cancer Detection and Reduces Recall Rates
Compared to traditional mammography, three-dimensional (3D) mammography—known as digital breast tomosynthesis—found 22% more breast cancers and led to fewer call-backs in a large screening study at the Hospital of the University of Pennsylvania, researchers reported today at the 99th...
U.S. Preventive Services Task Force Issues Final Recommendations on Screening for Oral Cancer
The U.S. Preventive Services Task Force (USPSTF) today released its final recommendation statement on screening for oral cancer in adults without signs or symptoms of oral cancer who are seen by primary care providers. This recommendation focuses on primary care professionals and is not a...
Certain Symptom Clusters After Surgery for Esophageal Cancer Predict Poor Prognosis
A new study has found that several months after surgery for esophageal cancer, different symptoms cluster together in different types of patients. In addition, patients with certain symptom clusters have an increased risk of dying from their disease. The findings by Wikman et al were published...
ASCO Endorses Cancer Care Ontario Guideline for Follow-up in Colorectal Cancer Survivors
ASCO has policy and procedures for endorsing clinical practice guidelines developed by other professional organizations. As reported in the Journal of Clinical Oncology by Meyerhardt et al of the ASCO Clinical Practice Guidelines Committee, ASCO has endorsed the Cancer Care Ontario (CCO)...
FDA Approves Sorafenib to Treat Late-Stage Differentiated Thyroid Cancer
The U.S. Food and Drug Administration today expanded the approved uses of sorafenib (Nexavar) to treat late-stage differentiated thyroid cancer. The new indication is for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to radioactive...
Study Finds Possible Link Between Allergies and Increased Risk of Hematologic Cancers in Women
A team of researchers looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies—in particular to plants, grass, and trees—with risk of blood cancers in women. The same association was not found in men, suggesting a possible...
Smoking Increases Risk of Death for Nasopharyngeal Carcinoma Survivors
Survivors of nasopharyngeal carcinoma who are former or current smokers are more likely to have their disease progress, relapse, or spread, and are more likely to die of their disease, compared with survivors of nasopharyngeal carcinoma who have never smoked, according to a study published in...
FDA Grants Regular Approval to Crizotinib for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) today granted regular approval for crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Today’s...
Tasquinimod May Improve Survival in Men With Metastatic Prostate Cancer
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
